In a bid to safeguard the lives of the citizen even as it concerns the use of drugs, the National Agency for Food and Drug Administration and Control (NAFDAC) has launched a mobile application, “Med Safety App” to report Adverse Drug Reactions (ADRs) that might occur while taking a drug.
Director-General of the agency, Mrs. Mojisola Adeyeye reportedly disclosed this at a virtual meeting aimed at commemorating the 2020 World Health Organization Medicine Safety Week by inaugurating the mobile app.
Adeyeye reportedly said that the best time to launch the app is now since the world is focused on the safety of medications used in healthcare delivery and the battle to tackle the COVID-19 pandemic.
Adeyeye reportedly said that the adoption of the `Med Safety App’ by Nigeria commenced in August 2019 when NAFDAC officially submitted an expression of interest to the World Health Organisation (WHO) at the 42nd Annual Meeting of Pharmacovigilance Centres held at Bagota, Colombia in October 2019.
According to Adeyeye, the National Pharmacovigilance Centre (NPC) had continually deployed hard copy ADR triplicate forms, e-reporting platforms, and the Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR) to collect and collate reports of ADRs.
Adeyeye lamented that ADRs and other drug-related problems remain under-reported in Nigeria and within the WHO region of Africa in spite of the availability of these Pharmacovigilance reporting tools.
“The Med Safety App is available for download for free on all android and apple smartphones and it provides a medium for users to report incidences of ADRs from the comfort of their homes”, Adeyeye reportedly said.
Adeyeye reportedly called on healthcare providers and Nigerians at large to download the App from the apple play store and use it to support NAFDAC to achieve the mandate of safeguarding the health of the nation.
Adeyeye reportedly said that the agency expected that the use of the App would promote awareness and increase the reportage of ADRs among healthcare professionals, healthcare providers, and the public.